

Santiago Escriva-de-Romani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1349083/publications.pdf>

Version: 2024-02-01

10
papers

338
citations

1477746

6
h-index

1372195

10
g-index

10
all docs

10
docs citations

10
times ranked

654
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Abstract OT2-27-01: Solti-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC). <i>Cancer Research</i> , 2022, 82, OT2-27-01-OT2-27-01. | 0.4 | 1 |
| 2 | Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. <i>Cancers</i> , 2020, 12, 3509. | 1.7 | 7 |
| 3 | Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 731-741. | 1.1 | 6 |
| 4 | Paraneoplastic cerebellar degeneration diagnosed by anti-Yo determination in a young woman with early breast cancer. <i>BMJ Case Reports</i> , 2020, 13, e233863. | 0.2 | 4 |
| 5 | Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. <i>Clinical Cancer Research</i> , 2020, 26, 5820-5829. | 3.2 | 68 |
| 6 | The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1. <i>Cancers</i> , 2020, 12, 670. | 1.7 | 31 |
| 7 | SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1000-1000. | 0.8 | 71 |
| 8 | Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1075-1075. | 0.8 | 2 |
| 9 | HER2-positive breast cancer: Current and new therapeutic strategies. <i>Breast</i> , 2018, 39, 80-88. | 0.9 | 89 |
| 10 | p95HER2â€™T cell bispecific antibody for breast cancer treatment. <i>Science Translational Medicine</i> , 2018, 10, . | 5.8 | 59 |